Skip to content

The Optimal Duration and Regimen of Supplemental Octreotide Therapy for Acute Pancreatitis

The Optimal Duration and Regimen of Supplemental Octreotide Therapy for Acute Pancreatitis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002506
Enrollment
Unknown
Registered
2012-09-12
Start date
2012-09-12
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pancreatitis

Interventions

C:general medical management
C+O3:general medical management+Octreotide iv 25ug/h *3days
C+O7:general medical management+Octreotide iv (50ug/h*3days +25ug/h *4days)
C+O7+O3h:general medical management+Octreotide iv (50ug/h*3days +25ug/h *4days) +Octreotide ih 100ug tid *3days

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with acute pancreatitis: showing obvious upper abdominal pain and serum amylase increased 3 times more than normal maximum level with/without enlargement of pancreas or peripancreatic fluid accumulation;with 2 of the upper symptoms; 2. Patients voluntarily signed the informed consent; 3. Age from 18-70 years old; 4. Admission within 72h from the onset of symptoms.

Exclusion criteria

Exclusion criteria: 1. Patients with other disease may impact the level of SST(such as acute leukimia etc); 2. Patients with respiratory/urinary/intestinal infections in nearly 2 weeks; 3. Women in pregnancy or lactation; 4. Patients with severe disease of heart, lung, brain, kidney; 5. Patients with long-term drug history and neuropsychiatric disorders.

Design outcomes

Primary

MeasureTime frame
TNF-alpha;IL-6;IL-10;APACHE II score;

Secondary

MeasureTime frame
CTSI;mortality;MOF score;incidence of organ failure;SST;length of stay;Ratio of MAP;Ratio of M-SAP;Ratio of SAP;incidence of local complication at 1m;

Countries

China

Contacts

Public ContactChengwei Tang
cwtang@medmail.com.cn+86 18980601275

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026